ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,116.05
      0.17%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Poseida Therapeutics Inc (PSTX)

      7. Poseida Therapeutics Inc (PSTX) News

      PSTX

      Poseida Therapeutics (PSTX)

      Poseida Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:PSTX
      DateTimeSourceHeadlineSymbolCompany
      06/03/20244:05PMPR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
      05/14/20244:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
      05/14/20244:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
      05/14/20244:05PMPR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
      05/09/20249:00AMPR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
      05/06/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
      05/01/20249:30PMPR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
      05/01/20243:25PMAllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
      05/01/20249:00AMPR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
      04/18/20248:00AMPR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
      04/17/20249:00AMPR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
      04/08/202412:00PMPR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
      04/01/20244:05PMPR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
      03/25/20244:05PMPR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
      03/19/20244:05PMPR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
      03/13/20244:05PMPR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
      03/07/20244:07PMPR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
      03/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
      03/04/20245:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
      03/04/20245:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
      03/04/20244:05PMPR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
      02/08/20244:10PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PSTXPoseida Therapeutics Inc
      01/04/20244:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
      01/04/20244:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
      01/04/20248:00AMPR Newswire (US)Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:PSTXPoseida Therapeutics Inc
      12/11/202310:31AMDow Jones NewsPoseida Therapeutics Shares Climb on Positive Data for Blood Cancer TreatmentNASDAQ:PSTXPoseida Therapeutics Inc
      12/11/20236:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
      12/10/202312:00PMPR Newswire (US)Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
      11/09/20234:11PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
      11/09/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:PSTX